Lexeo Therapeutics, Inc. (LXEO)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 42/100 (MEDIUM), 25.8 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 40.51% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
- Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)
- Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
- Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
- Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September
- Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights
- What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple
- Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update?
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Lexeo Therapeutics, Inc..
Full LXEO Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.